Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)
Close on Nov 17, 2026Market cap $50.42MP/E –Yield –
Tonix Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Tonix Pharmaceuticals's total debt was $7.49M at Dec 31, 2024. For fiscal 2024 it was $7.49M, down 16.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.49M | -16.0% |
| FY2023 | Dec 31, 2023 | $8.91M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $7.49M | -16.0% |
| Q3 FY2024 | Sep 30, 2024 | $7.99M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.49M | – |
| Q1 FY2024 | Mar 31, 2024 | $8.98M | – |
| Q4 FY2023 | Dec 31, 2023 | $8.91M | – |
See a number that looks wrong?